Rare diseases
Investigational molecules
Locations
Calle Balmes 89 Planta 1 Puerta 2, 08008 Barcelona, Spain
Research activity is centered on advanced and metastatic HER2-positive breast cancer, including disease that has progressed after prior trastuzumab-based treatment. The sponsor also funds studies in locally advanced settings and in patients receiving HER2-targeted therapy combined with other systemic approaches.
These trials include biomarker-linked work in ERBB2 expression and treatment-sensitive subgroups within HER2-positive disease.
Solti Group runs clinical trials in conditions such as Hormone receptor positive HER2 negative breast cancer, HER2 positive breast cancer, Metastatic neoplasm, Hormone receptor positive breast cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceSpainSpain
PortugalFranceSpainSpainSpainSpainSpainSpainSpainIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
